See Full Prescribing Facts OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed right after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or right after 3 or even more strains of systemic therapy that includes autologous